LIPA works with lawmakers in the US Congress as well as organizations on the national level to ensure that the role of independent pharmacies not only survives, but thrives for years to come.
We are committed to progressively correcting the damaging influence exerted in the past decade by the uncontrolled expansion of PBMs. By working in Congress and the Legislature and supporting our national partners, we strive to assure that these entities are repositioned into a more appropriate role—that of supporting the needs of pharmaceutical distribution without being intrusive into the care of patients provided by licensed health care professionals.
Health and Human Services Proposed Rule:
Comment Period Open Until April 8, 2019
Summary: In this proposed rule, the Department of Health and Human Services (Department or HHS) proposes to amend the safe harbor regulation concerning discounts, which are defined as certain conduct that is protected from liability under the Federal anti-kickback statute, section 1128B(b) of the Social Security Act (the Act). The amendment would revise the discount safe harbor to explicitly exclude from the definition of a discount eligible for safe harbor protection certain reductions in price or other remuneration from a manufacturer of prescription pharmaceutical products to plan sponsors under Medicare Part D, Medicaid managed care organizations as defined under section 1903(m) of the Act (Medicaid MCOs), or pharmacy benefit managers (PBMs) under contract with them. In addition, the Department is proposing two new safe harbors. The first would protect certain point-of-sale reductions in price on prescription pharmaceutical products... Read more ...
To submit a comment, click on green "Submit Formal Comment" button at top of page or click here.
Previous Federal Pharmacy Legislation
H.R. 244 - MAC Transparency Act of 2015
Summary: H.R. 244 is a bipartisan bill that would ensure federal health plan reimbursements to pharmacies keep pace with generic drug prices, many which skyrocket overnight. This bill would provide transparency and fairness to community pharmacies regarding their reimbursement for generic drugs. This bill would require pharmacy benefit managers (PBMs) to disclose the rate of reimbursement in the contract and to update that rate at least once every seven days to reflect fluctuations in the market.
Summary: Provider Status Legislation—these companion bills would recognize pharmacists as providers under the Medicare Part B program. If enacted, pharmacists would be able to perform services for patients consistent with their state’s scope of practice if their pharmacy is located in a medically underserved area, health professional shortage area, or medically underserved population.
Summary: These companion bills would give independent pharmacies the ability to participate in preferred networks if one or more of their stores is located in a health professional shortage area, one or more of their stores is located in a medically underserved population, and if they can meet the terms and conditions that are offered to other in-network pharmacies.